Navigation Links
Study identifies key cause of chronic leukemia progression
Date:3/4/2010

COLUMBUS, Ohio Researchers have discovered a key reason why a form of leukemia progresses from its more-treatable chronic phase to a life-threatening phase called blast crisis.

The study, led by cancer researchers at the Ohio State University Comprehensive Cancer Center-Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC-James), indicates that chronic myeloid leukemia (CML) progresses when immature white blood cells lose a molecule called miR-328.

Loss of the molecule traps the cells in a rapidly growing, immature state. The cells soon fill the bone marrow and spill into the bloodstream, a tell-tale sign that the disease has advanced to the blast crisis stage.

The research, published in the March 5th issue of the journal Cell, should provide a better understanding of the blast-crisis stage of CML, and it suggests a possible new treatment strategy for the disease, the researchers say.

"These findings indicate that the loss of miR-328 is probably essential for progression from the chronic phase of the disease to the blast crisis stage," says principal investigator Danilo Perrotti, associate professor of molecular virology, immunology and medical genetics and a member of the OSUCCC-James.

"Our findings also suggest that maintaining the level of this microRNA might represent a new therapeutic strategy for CML blast crisis patients who do not benefit from targeted agents such as imatinib (Gleevec) and dasatinib (Sprycel)," Perrotti says

The study also revealed a new function for microRNA. Researchers have known for some time that these molecules help regulate the kinds of proteins that cells make. But this study shows for the first time that microRNA molecules can also attach directly to protein molecules and alter their function.

In this case, miR-328 binds to a protein that prevents immature blood cells from maturing. "We believe that it normally acts as a decoy molecule, tying up the protein and enabling the white blood cells to mature as they should," Perrotti says.

During CML progression, however, the level of miR-328 drops, allowing the protein to be extremely active. This keeps the leukemic white blood cells from maturing and contributes to the transition from the chronic-disease phase to blast crisis phase.

"These findings may help unravel novel pathways responsible for the initiation and progression of leukemia generally," Perrotti says.


'/>"/>

Contact: Darrell E. Ward
Darrell.Ward@osumc.edu
614-293-3737
Ohio State University Medical Center
Source:Eurekalert

Related biology news :

1. Study shows woody plant encroachment has increased stream flow in the Edwards Plateau
2. New study shows teens who drink 100 percent fruit juice have more nutritious diets overall
3. Study: Climate change one factor in malaria spread
4. Kids lose pounds, gain fitness in Houston study
5. An apple a day? Study shows soluble fiber boosts immune system
6. MMS and NOAA scientists study prey of Gulf of Mexico sperm whales
7. Study finds dirty air in California causes millions worth of medical care each year
8. New technique allows study of protein folding, dynamics in living cells
9. Study: Gene therapy reverses effects of lethal childhood muscle disorder in mice
10. UAB study shows African-Americans have highest stroke rate, southerners more likely to die
11. New University of Colorado paper shows novel way to study human inflammatory disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/30/2016)...  higi SH llc (higi) announced today the ... brands, industry thought-leaders and celebrity influencers looking to ... taking steps to live healthier, more active lives. ... has built the largest self-screening health station network ... who have conducted over 185 million biometric screenings.  ...
(Date:11/29/2016)... 29, 2016 Nearly one billion matches per second ... ... DERMALOG is Germany's ... efficient Identity Management. (PRNewsFoto/DERMALOG Identification Systems) ... DERMALOG is Germany's largest Multi-Biometric supplier: The company's Fingerprint Identification ...
(Date:11/22/2016)... PUNE, India , November 22, 2016 According ... (Single-Factor: (Fingerprint, IRIS, Palm Print, Face, Vein, Signature, Voice), Multi-Factor), Component (Hardware ... to 2022", published by MarketsandMarkets, the market is expected to grow from ... at a CAGR of 16.79% between 2016 and 2022. ... ...
Breaking Biology News(10 mins):
(Date:12/9/2016)... ... ... There’s a winning streak at Voxx Analytics: the tech company has been ... award last year as well. Employees nominate their companies for the honor, and this ... the tech company’s upbeat environment as a reason. “We don’t answer to Wall Street. ...
(Date:12/9/2016)... ... , ... Aditya Humad, Acting CFO of AxioMed and Managing Partner of KICVentures, ... Axiomed is now gaining interest from Silicon Valley. “It was satisfying to complete the ... to say that, “We expect interest to continue to rise as AxioMed completes its ...
(Date:12/9/2016)... 9, 2016  A platform of orthopedic device technologies ... one step closer to becoming viable options for ... Inc., a start-up company from Philadelphia, ... for these novel absorbable bone fixation and regenerative ... commercial use. The company has leased space within ...
(Date:12/9/2016)... , Dec. 9, 2016 /PRNewswire/ - Portage Biotech Inc. ... PBT.U), is pleased to announce that Biohaven has issued ... New Haven, Connecticut (PRWEB) Dec 9, 2016 ... "Biohaven") announced today that the U.S. Food and Drug ... request covering its drug candidate BHV-0223, an orally dissolving ...
Breaking Biology Technology: